These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20598622)

  • 21. Motor fluctuations and dyskinesia in Parkinson's disease.
    Nutt JG
    Parkinsonism Relat Disord; 2001 Oct; 8(2):101-8. PubMed ID: 11489675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 25. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk factors associated with the development of motor complications in Parkinson's disease. A study in a Chilean population].
    Juri-Claveria C; Aguirre-M C; Viviani-G P; Chana-Cuevas P
    Rev Neurol; 2007 Jul 16-31; 45(2):77-80. PubMed ID: 17642046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 35. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
    Müller T; Woitalla D; Russ H; Hock K; Haeger DA
    J Neural Transm (Vienna); 2007; 114(8):1023-6. PubMed ID: 17417738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dyskinesias of the tongue and other face structures].
    Lewandowski L; Osmola K; Grodzki J
    Ann Acad Med Stetin; 2006; 52 Suppl 3():61-3. PubMed ID: 17939202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
    Nakamura Y; Yoshinaga J; Endo S; Hikiji A
    Rinsho Shinkeigaku; 1997 Jun; 37(6):469-75. PubMed ID: 9366172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.